Drug intelligence / Profile preview

CAR-BCMA

Development stage: Phase 2
Lead developer: National Cancer Institute
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CAR-BCMA is an autologous chimeric antigen receptor (CAR) T-cell therapy engineered to target B-cell maturation antigen (BCMA), a protein consistently expressed on malignant plasma cells in multiple myeloma (MM). This therapy involves genetically modifying a patient's own T cells to express a CAR that specifically recognizes and eliminates BCMA-expressing cells. Developed in part by the National Cancer Institute, it has been evaluated in a first-in-human Phase 1 clinical trial for patients with relapsed/refractory MM.

Other names: anti-BCMA CAR T cells

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on CAR-BCMA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAR-BCMA.

Explore the full profile